Kazuyoshi Nakamura

Kimitsu, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer.

Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer.

Journal: Anticancer research
Published: March 17, 2026

Full-Component Chart-Derived Lee Score, Upfront Androgen Receptor Signaling Inhibitor Selection, and Competing Mortality in Metastatic Hormone-Sensitive Prostate Cancer.

Full-Component Chart-Derived Lee Score, Upfront Androgen Receptor Signaling Inhibitor Selection, and Competing Mortality in Metastatic Hormone-Sensitive Prostate Cancer.

Journal: Geriatrics & gerontology international
Published: February 26, 2026

Tumor-draining lymph nodes as immunologic hubs: rethinking nodal surgery in the era of checkpoint blockade in urologic cancers.

Tumor-draining lymph nodes as immunologic hubs: rethinking nodal surgery in the era of checkpoint blockade in urologic cancers.

Journal: International urology and nephrology
Published: February 06, 2026

A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.

A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.

Journal: The Prostate
Published: February 03, 2026

Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report.

Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report.

Journal: Anticancer research
Published: December 18, 2025

Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.

Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.

Journal: BJU international
Published: November 13, 2025

Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy.

Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy.

Journal: Anticancer research
Published: October 28, 2025

Prognostic significance of nutritional and muscular indices in immune checkpoint inhibitor therapy for metastatic urothelial carcinoma: A preliminary study.

Prognostic significance of nutritional and muscular indices in immune checkpoint inhibitor therapy for metastatic urothelial carcinoma: A preliminary study.

Journal: Nutrition (Burbank, Los Angeles County, Calif.)
Published: September 09, 2025

Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer: Results From a 3-Year Interim Analysis of the J-ROCK Study.

Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer: Results From a 3-Year Interim Analysis of the J-ROCK Study.

Journal: The Prostate
Published: September 03, 2025

Multimodal Artificial Intelligence Using Endoscopic USG, CT, and MRI to Differentiate Between Serous and Mucinous Cystic Neoplasms.

Multimodal Artificial Intelligence Using Endoscopic USG, CT, and MRI to Differentiate Between Serous and Mucinous Cystic Neoplasms.

Journal: Cureus
Published: June 07, 2025

Impact of Age on Treatment Patterns and Outcomes in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.

Impact of Age on Treatment Patterns and Outcomes in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.

Journal: International journal of urology : official journal of the Japanese Urological Association
Published: June 02, 2025

Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer.

Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer.

Journal: Cancer genetics
Published: May 30, 2025
Showing 1-12 of 55

Last Updated: 09/26/2026